Reviews

Research progress of left ventricular function in metabolic syndrome

  • ZHOU Qinghua
Expand
  • Aviation General Hospital of China Medical University; Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing 100021, China

Received date: 2015-03-11

  Revised date: 2015-09-30

  Online published: 2016-02-04

Abstract

The definition and clinical diagnostic criteria of metabolic syndrome (MS) are elaborated in this paper. The feature of left ventricular cardiac function changes of MS is identified through understanding of the relationships between hypertension, dyslipidemia, obesity, blood glucose abnormalities and left ventricular cardiac function. Decreased left ventricular function in patients with MS is caused by a number of cardiovascular risk factors, which lead to a number of complex metabolic reactions, affect the structure and metabolism of the myocardial environment and change the cardiac function and myocardial energy. Therefore, prior to development of symptomatic heart failure, MS patients may experience a period of subclinical left ventricular dysfunction.

Cite this article

ZHOU Qinghua . Research progress of left ventricular function in metabolic syndrome[J]. Science & Technology Review, 2016 , 34(2) : 76 -80 . DOI: 10.3981/j.issn.1000-7857.2016.2.011

References

[1] Panel N C E P N E. Third report of the national cholesterol education pro-gram (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report[J]. Circu-lation, 2002, 106(25): 3143.
[2] Alberti K G M M, Zimmet P, Shaw J, et al. The metabolic syndrome-a new worldwide definition[J]. The Lancet, 2005, 366(9491): 1059-1062.
[3] Seo J M, Park T H, Lee D Y, et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension[J]. Journal of cardiovas-cular ultrasound, 2011, 19(3): 134-139.
[4] D'hooge J, Heimdal A, Jamal F, et al. Regional strain and strain rate mea-surements by cardiac ultrasound: Principles, implementation and limita-tions[J]. European Heart Journal-Cardiovascular Imaging, 2000, 1(3): 154-170.
[5] Adamu G U, Katibi A I, Opadijo G, et al. Prevalence of left ventricular di-astolic dysfunction in newly diagnosed Nigerians with systemic hyperten-sion: a pulsed wave Doppler echocardiographic study[J]. African Health Sciences, 2010, 10(2): 177-182.
[6] Chen G L, Wang M J, Liu J M, et al. Association between left ventricular diastolic function and blood pressure variability in essential hypertensive patients[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2013, 41(8): 683-686.
[7] 卢志华, 郭瑞强, 陈金玲, 等. 二维超声斑点追踪成像技术评价正常构型原发性高血压患者左心室收缩功能[J]. 武汉大学学报: 医学版, 2010 (3): 347-350. Lu Zhihua, Guo Ruixian, Chen Jingling, et al. Two dimensioal speckle tarckingimaging in assessment of left ventricular function in essential hy-pertension with normal ventricular geometry[J]. Medical Journal of Wu-han University, 2010, 31(3): 347-350.
[8] 刘蓉, 邓又斌, 余芬, 等. 超声斑点追踪二维应变评价原发性高血压患者左室心内膜下心肌收缩功能[J]. 中国超声医学杂志, 2009, 25(7): 653-656. Liu Rong, Deng Youbing, Yu Feng, et al. Two dimensioal speckle tarck-ing imaging in assessment of left ventricular endocardial systolic function in essential hypertension[J]. China Journal of Ultrasound Medicine, 2009, 25(7): 653-656.
[9] Weber K T, Brilla C G, Janicki J S. Myocardial fibrosis: functional signifi-cance and regulatory factors[J]. Cardiovascular research, 1993, 27(3): 341-348.
[10] Dodiyi-Manuel S T, Akpa M R, Odia O J. Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria[J]. Vas-cular Health and Risk Management, 2013, 9: 529.
[11] 阴海霞, 龚渭冰, 刘爱玲, 等. 应变率成像及背向散射积分技术对糖尿病患者心肌局部舒张功能的研究[J]. 放射学实践, 2009, 24(3): 334-337. Yin Haixia, Gong Weibing, Liu Ailing, et al. Study of myocardial region-al diastolic function in diabetes patients by strain rate imaging and inte-grated bachscater techniques[J]. Radiology Practice 2009, 24(3): 334-338.
[12] 施曼珠. 糖尿病与心脏病[J]. 中华内科杂志, 1995, 34(9): 581-582. Shi Manzhu. Diabeties metilus and heart disease[J]. Chinese Journal of Internal Medicine, 1995, 34(9): 581-582.
[13] Haffner S M, Miettinen H. Insulin resistance implications for type II dia-betes mellitus and coronary heart disease[J]. The American Journal of Medicine, 1997, 103(2): 152-162.
[14] Braunwald E. Heart disease: A text book of cardiovascular medicine. [M]. 9th ed. WB: Sounders, 2013.
[15] Rubinstein J, Pelosi A, Vedre A, et al. Hypercholesterolemia and myo-cardial function evaluated via tissue doppler imaging[J]. Cardiovascular Ultrasound, 2009, 7(1): 56.
[16] Masoudi F A, Inzucchi S E. Diabetes mellitus and heart failure: Epidemi-ology, mechanisms, and pharmacotherapy[J]. The American Journal of Cardiology, 2007, 99(4): 113-132.
[17] Dabestani A, Child J S, Perloff J K, et al. Cardiac abnormalities in prima-ry hemochromatosis[J]. Annals of the New York Academy of Sciences, 1988, 526(1): 234-244.
[18] Ashrafian H, Frenneaux M P, Opie L H. Metabolic mechanisms in heart failure[J]. Circulation, 2007, 116(4): 434-448.
[19] O'Keefe J H, Gheewala N M, O'Keefe J O. Dietary strategies for improv-ing post-prandial glucose, lipids, inflammation, and cardiovascular health[J]. Journal of the American College of Cardiology, 2008, 51(3): 249-255.
[20] Poornima I G, Parikh P, Shannon R P. Diabetic cardiomyopathy the search for a unifying hypothesis[J]. Circulation Research, 2006, 98(5): 596-605.
[21] Rader D J. Effect of insulin resistance, dyslipidemia, and intra-abdomi-nal adiposity on the development of cardiovascular disease and diabetes mellitus[J]. The American Journal of Medicine, 2007, 120(3): S12-S18.
[22] Berg A H, Scherer P E. Adipose tissue, inflammation, and cardiovascu-lar disease[J]. Circulation Research, 2005, 96(9): 939-949.
[23] Regitz-Zagrosek V, Lehmkuhl E, Weickert M O. Gender differences in the metabolic syndrome and their role for cardiovascular disease[J]. Clin-ical Research in Cardiology, 2006, 95(3): 136-147.
[24] Saltevo J, Vanhala M, Kautiainen H, et al. Gender differences in C-reac-tive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study[J]. Diabetic Medi-cine, 2008, 25(6): 747-750.
[25] Kossaify A, Nicolas N. Impact of overweight and obesity on left ventricu-lar diastolic function and value of tissue Doppler echocardiography[J]. Clinical Medicine Insights, Cardiology, 2013, 7: 43.
[26] Ahn M S, Kim J Y, Youn Y J, et al. Cardiovascular parameters correlated with metabolic syndrome in a rural community cohort of Korea: the ARI-RANG study[J]. Journal of Korean Medical Science, 2010, 25(7): 1045-1052.
[27] Ruberg F L, Chen Z, Hua N, et al. The relationship of ectopic lipid accu-mulation to cardiac and vascular function in obesity and metabolic syn-drome[J]. Obesity, 2010, 18(6): 1116-1121.
[28] McGavock J M, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes melli-tus A 1H-magnetic resonance spectroscopy study[J]. Circulation, 2007, 116(10): 1170-1175.
[29] Karamitsos T D, Karvounis H I, Didangelos T, et al. Impact of autonomic neuropathy on left ventricular function in normotensive type 1 diabetic patients a tissue doppler echocardiographic study[J]. Diabetes Care, 2008, 31(2): 325-327.
[30] Van Heerebeek L, Hamdani N, Handoko M L, et al. Diastolic stiffness of the failing diabetic heart importance of fibrosis, advanced glycation end products, and myocyte resting tension[J]. Circulation, 2008, 117(1): 43-51.
[31] Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiff-ness in heart failure with normal ejection fraction[J]. Circulation, 2008, 117(16): 2051-2060.
[32] Rijzewijk L J, van der Meer R W, Smit J W A, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus[J]. Journal of the American College of Cardiology, 2008, 52(22): 1793-1799.
[33] Von Bibra H, Sutton M S J. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis[J]. Diabetologia, 2010, 53(6): 1033-1045.
Outlines

/